Live Analyst Rating Changes 22261 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Evan Seigerman
BMO

Evan Seigerman

BMO Capital
Wall Street Analyst
★★★★☆
#468
on 13Foresight · ranked by our own returns
69%
Success Rate
+4.6%
Average Return
71 of 103 calls profitable · +0.5% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 69% of Evan Seigerman's ratings turned a profit when each position was held for 1 year — averaging +4.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

180 Buy 78 Hold 12 Sell
Evan's Stock Coverage 37 ratings · 2026-08-10
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
REPL
Replimune Group
 Aug 07, 2026 BUY Strong Buy
+80.0% avg upside
14 analysts
$20.00
51.47% Upside
 · ·
SRRK
Scholar Rock Holding
 Aug 07, 2026 BUY Strong Buy
+9.6% avg upside
23 analysts
$76.00
46.04% Upside
 -1.9% ·
LLY
Eli Lilly & Co
 Aug 06, 2026 BUY Strong Buy
-12.3% avg upside
48 analysts
$1400.00
16.34% Upside
 -0.5% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Aug 06, 2026 BUY Strong Buy
+95.9% avg upside
17 analysts
$145.00
172.03% Upside
 +2.3% ·
GILD
Gilead Sciences
 Aug 06, 2026 BUY Strong Buy
-10.8% avg upside
66 analysts
$174.00
29.61% Upside
 +1.7% ·
MRK
Merck & Company
 Aug 05, 2026 BUY Strong Buy
+0.2% avg upside
43 analysts
$142.00
10.19% Upside
 +0.2% ·
SDGR
Schrodinger
 Aug 05, 2026 BUY Strong Buy
+55.9% avg upside
14 analysts
$24.00
32.98% Upside
 +10.7% ·
BNTX
BioNTech SE
 Aug 05, 2026 BUY Strong Buy
+42.8% avg upside
26 analysts
$128.00
36.28% Upside
 +1.2% ·
NVO
Novo Nordisk
 Aug 05, 2026 HOLD Buy
+145.5% avg upside
26 analysts
$47.00
0.27% Upside
 +6.1% ·
AMGN
Amgen
 Aug 05, 2026 BUY Buy
-23.3% avg upside
57 analysts
$450.00
9.76% Upside
 +2.3% ·
PFE
Pfizer
 Aug 04, 2026 BUY Buy
+24.7% avg upside
45 analysts
$30.00
12.37% Upside
 +6.5% ·
REGN
Regeneron
 Jul 31, 2026 BUY Strong Buy
-0.6% avg upside
58 analysts
$800.00
0.85% Upside
 +2.9% ·
BIIB
Biogen
 Jul 30, 2026 HOLD Strong Buy
+21.6% avg upside
52 analysts
$208.00
0.33% Downside
 +0.0% ·
INCY
Incyte
 Jul 29, 2026 HOLD Buy
-11.1% avg upside
47 analysts
$130.00
7.06% Upside
 -5.1% ·
MPLT
MapLight Therapeutics, Inc.
 Jul 27, 2026 BUY Strong Buy
+141.8% avg upside
13 analysts
$20.00
64.21% Upside
 +23.0% ·
BMY
Bristol-Myers Squibb
 Jul 27, 2026 HOLD Buy
-5.8% avg upside
42 analysts
$60.00
6.71% Downside
 +3.5% ·
NBIX
Neurocrine
 Jul 13, 2026 HOLD Strong Buy
+14.9% avg upside
37 analysts
$170.00
4.44% Upside
 -6.1% ·
VRTX
Vertex Pharmaceuticals
 Jul 13, 2026 BUY Strong Buy
-12.0% avg upside
62 analysts
$600.00
13.31% Upside
 +3.3% ·
ABBV
AbbVie
 Jul 13, 2026 BUY Strong Buy
-3.1% avg upside
46 analysts
$300.00
21.89% Upside
 +0.7% ·
TSE:APTX
Apotex Health Corp.
 Jul 06, 2026 BUY Strong Buy
+6.8% avg upside
10 analysts
$39.00
3.56% Upside
 +8.0% ·
TSHA
Taysha Gene Therapies
 Jun 30, 2026 BUY Strong Buy
+112.0% avg upside
21 analysts
$14.00
113.72% Upside
 -6.5% ·
ABCL
AbCellera Biologics
 Jun 17, 2026 BUY Strong Buy
+82.8% avg upside
15 analysts
$7.00
23.86% Downside
 +27.4% ·
IRON
Disc Medicine
 Jun 02, 2026 BUY Strong Buy
+12.2% avg upside
21 analysts
$100.00
29.14% Upside
 +13.9% ·
ACAD
ACADIA Pharmaceuticals
 May 11, 2026 BUY Strong Buy
+24.5% avg upside
43 analysts
$34.00
16.17% Upside
 +16.7% ·
PTGX
Protagonist Therapeutics
 Oct 13, 2025 BUY Strong Buy
-23.9% avg upside
19 analysts
$112.00
25.28% Downside
 +86.6% ·
NGNE
Neurogene
 Sep 30, 2025 HOLD Strong Buy
+37.8% avg upside
23 analysts
 — +105.9% ·
ARVN
Arvinas Holding Company
 Sep 30, 2025 HOLD Buy
+226.7% avg upside
28 analysts
 — +5.1% ·
CCCC
C4 Therapeutics
 May 06, 2025 HOLD Strong Buy
+380.3% avg upside
19 analysts
 — +107.8% ·
DE:MRK
Merck KGaA
 Oct 23, 2024 BUY Buy
-4.8% avg upside
33 analysts
$129.82
9.67% Downside
 -24.6% ·
CADL
Candel Therapeutics
 Aug 07, 2023 HOLD Strong Buy
+72.8% avg upside
11 analysts
 — +369.2% ·
NUVB
Nuvation Bio
 May 09, 2023 HOLD Strong Buy
+103.6% avg upside
15 analysts
 — +106.8% ·
IMA
ImageneBio
 Aug 13, 2021 BUY Buy
+196.5% avg upside
12 analysts
$27.00
374.49% Upside
 · ·
OBX
Obsidian Therapeutics
 Dec 16, 2020 BUY Buy
-65.6% avg upside
9 analysts
$15.00
45.70% Downside
 · ·
NL:LKFT
Galapagos
 Oct 16, 2020 HOLD Sell
+123.5% avg upside
16 analysts
$129.00
449.04% Upside
 -58.7% ·
TLPH
Talphera
 Aug 13, 2020 SELL Buy
+230.2% avg upside
15 analysts
$0.84
41.34% Downside
 · ·
MGNX
MacroGenics
 May 11, 2020 BUY Buy
+335.6% avg upside
25 analysts
$30.00
637.19% Upside
 +16.1% ·
LKFT
Lakefront Biotherapeutics
 Feb 24, 2020 HOLD Buy
+292.8% avg upside
24 analysts
$220.00
714.30% Upside
 -65.5% ·
🔒 32 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Evan Seigerman — Frequently Asked Questions
How accurate are Evan Seigerman's stock ratings?
Based on the calls 13Foresight could measure, about 68% of Evan's ratings were profitable over a one-year hold, with an average return of +4.5% per rating, or +0.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Evan ranked on 13Foresight?
Evan Seigerman is currently ranked #468 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Evan cover?
Evan most recently has ratings on REPL, SRRK, LLY, GPCR, GILD, MRK, SDGR, BNTX, NVO, AMGN, PFE, REGN and 25 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.